Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Cardiac muscle hypertrophies in response to increased blood pressure or metabolic stress. But rather than being beneficial, as with exercise or pregnancy, the sort of growth that occurs is harmful to cardiac performance and viability, and may lead to heart failure. In fact, pathological hypertrophy is a strong predictor of morbidity and mortality. Preventing or reversing adverse cardiac remodeling is proven to be beneficial. While beta blockers and ACE inhibitors are effective in this regard, there is a clear need for additional therapeutic approaches. In their comprehensive review that appears in this issue (Targeting Cardiac Hypertrophy - Towards Causal Heart Failure Therapy), Dr. Heinzel and colleagues discuss novel drug approaches for tackling cardiac hypertrophy and heart failure in the context of the various signaling pathways that feed into maladaptive growth. These include third generation aldosterone antagonists, aldosterone synthesis inhibitors, ACE2 and Mas receptor agonists, and biased angiotensin II AT1 receptor agonists. Exploiting endogenous cGMP-protective signaling is another strategy ripe for exploration that has already shown promise with a combination vasopeptidase neprilysin inhibitor and AT1 receptor blocker (ARNi). Lastly, Dr. Heinzel and colleagues discuss promising novel molecular genetic approaches to revitalize cardiac muscle.
-George Booz, JCVP Associate Editor
View current Drugs in the Pipeline article here
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Journal of Cardiovascular Pharmacology.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
Save my selection
Smrcka, Alan V.
Smrcka, Alan V. Less
Journal of Cardiovascular Pharmacology. 65(3):203-210, March 2015.
Matavelli, Luis C.; Siragy, Helmy M.
Matavelli, Luis C.; Siragy, Helmy M. Less
Journal of Cardiovascular Pharmacology. 65(3):226-232, March 2015.
Helske-Suihko, Satu; Laine, Mika; Lommi, Jyri; More
Helske-Suihko, Satu; Laine, Mika; Lommi, Jyri; Kaartinen, Maija; Werkkala, Kalervo; Kovanen, Petri T.; Kupari, Markku Less
Journal of Cardiovascular Pharmacology. 65(3):233-240, March 2015.
Wu, Bo-Wei Less
Journal of Cardiovascular Pharmacology. 65(3):296, March 2015.
Login with your LWW Journals username and password.
Username or Email:
Need to Activate a New Subscription?Recently purchased a subscription? Login or Register a new account
and enter your subscription ID, or Subscribe Now!
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
View All Featured Jobs